
Location : Hammersmith, UK
Reporting to Senior Manager, Facilities and Laboratory Operations
Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on transforming the lives of patients with rare disorders through innovative gene therapies based on gene-modified hematopoietic stem cells (HSCs). Orchard has its global headquarters in London, England, and its U.S. headquarters in Boston, Massachusetts.
We are seeking an experienced and proactive Health, Safety & Compliance Specialist to support all aspects of health & safety, regulatory compliance, and biological safety across the organisation. This role will serve as the company’s appointed Biological Safety Officer (BSO) and will ensure full compliance with UK health & safety legislation, biological safety regulations, and internal governance standards. The successful candidate must have demonstrable experience managing health, safety and compliance within a regulated environment.
Key Responsibilities
Health & Safety
Biological Safety Officer (BSO) Duties
Compliance & Governance
Training & Culture
Requirements
Education / Key Competencies
Skills & Competencies
Orchard is an equal opportunity employer. We recognise and celebrate the diverse culture of our workforce and are committed to creating an inclusive environment for our employees. We fully support the principle of Equality and Diversity in employment and oppose all forms of unlawful or unfair discrimination. We assess all applications on basis of job requirements and individual qualifications.
We work within the requirements of all current legislation and we implement the provisions of regulatory codes of practice in employment.
Notice to All Applicants: Orchard Therapeutics participates in E-Verify

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.
Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
For more information, please visit https://www.orchard-tx.com/.